Press-release for stocks related to als for clnn

Prices are updated after-hours

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -26.62% | O: 2.33% H: 1.69% C: -6.56%
au8 als treatment

| -35.92% | O: -34.37% H: 3.49% C: -6.8%
au8 label als biomarker treatment extension trial platform

Clene Provides Update on ALS Clinical Development Meeting With FDA
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -35.92% | O: -34.37% H: 3.49% C: -6.8%
fda als update meeting

| -33.21% | O: 4.43% H: 27.91% C: 5.31%
au8 drug health als awards research grant study

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Published: 2023-10-05 (Crawled : 14:30) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -33.21% | O: 4.43% H: 27.91% C: 5.31%
au8 health als awards grant study

| -28.73% | O: 4.51% H: 9.53% C: -4.11%
cnm-au8 als treatment trial platform

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -58.75% | O: 1.9% H: 3.04% C: -1.86%
au8 als publication treatment phase 2

| -68.57% | O: -20.0% H: 14.88% C: 1.44%
au8 als trial platform

| -65.26% | O: -1.41% H: 5.72% C: 1.5%
au8 als meeting

| -69.72% | O: 0.92% H: 0.0% C: -1.82%
au8 als meeting

| -74.62% | O: 10.0% H: 0.7% C: -5.59%
au8 six als trial platform

Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -74.62% | O: 10.0% H: 0.7% C: -5.59%
treatment als back positive

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Published: 2023-03-08 (Crawled : 03:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -74.62% | O: 10.0% H: 0.7% C: -5.59%
au8 als trial platform

| -72.5% | O: 6.67% H: 1.56% C: 0.0%
au8 rescue-als disease extension als trial show

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
Published: 2022-10-03 (Crawled : 14:20) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -88.21% | O: -37.14% H: 21.59% C: 14.2%
au8 topline als trial platform cnm-au8

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Published: 2022-09-30 (Crawled : 22:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| Email alert Add to watchlist
report topline als trial results platform

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
Published: 2022-07-19 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -93.17% | O: -3.52% H: 4.29% C: 0.43%
au8 treatment designation drug ema als positive cnm-au8

Clene's ALS Drug Increases Survival by 70% in Mid-stage Study
Published: 2022-07-14 (Crawled : 17:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -88.54% | O: 7.64% H: 38.71% C: 33.23%
drug als study

Amylyx Augments Case for ALS Drug Ahead of PDUFA Date
Published: 2022-05-05 (Crawled : 22:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M

| -89.49% | O: 0.0% H: 0.32% C: -7.96%
drug pdufa als

Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market
Published: 2022-03-31 (Crawled : 05:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M